ZyVersa Therapeutics (ZyVersa Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 09, 2024)

View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics 5-Year Yield-on-Cost %?

ZyVersa Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.

The historical rank and industry rank for ZyVersa Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:

ZVSA's 5-Year Yield-on-Cost % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.87
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of ZyVersa Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, ZyVersa Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZyVersa Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's 5-Year Yield-on-Cost % falls into.

ZyVersa Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of ZyVersa Therapeutics is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

ZyVersa Therapeutics (NAS:ZVSA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

ZyVersa Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of ZyVersa Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

ZyVersa Therapeutics (ZyVersa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326

Website

https://www.zyversa.com

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Executives

Pablo A. Guzman	officer: Chief Medical Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover	director, officer: Chief Executive Officer	108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr.	officer: Chief Scientific Officer	C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe	officer: Chief Financial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere	officer: Chief Commercial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park	director	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd.	10 percent owner	4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones	director, officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor	director, officer: Chief Executive Officer	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp.	10 percent owner	88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880